. Delivery of arginine to eNOS by cationic amino acid transporter-1 (CAT-1) was shown to modulate eNOS activity. We found in female rats, but not in males, that CAT-1 activity is preserved with age and in chronic renal failure, two experimental models of ECD. In contrast, during pregnancy CAT-1 is inhibited. We hypothesize that female sex hormones regulate arginine transport. Arginine uptake in human umbilical vein endothelial cells (HUVEC) was determined following incubation with either 17␤-estradiol (E 2) or progesterone. Exposure to E2 (50 and 100 nM) for 30 min resulted in a significant increase in arginine transport and reduction in phosphorylated CAT-1 (the inactive form) protein content. This was coupled with a decrease in phosphorylated MAPK/extracellular signal-regulated kinase (ERK) 1/2. Progesterone (1 and 100 pM for 30 min) attenuated arginine uptake and increased phosphorylated CAT-1, phosphorylated protein kinase C␣ (PKC␣), and phosphorylated ERK1/2 protein content. GO-6976 (PKC␣ inhibitor) prevented the progesterone-induced decrease in arginine transport. Coincubation with both progesterone and estrogen for 30 min resulted in attenuated arginine transport. While estradiol increases arginine transport and CAT-1 activity through modulation of constitutive signaling transduction pathways involving ERK, progesterone inhibits arginine transport and CAT-1 via both PKC␣ and ERK1/2 phosphorylation, an effect that predominates over estradiol. estrogen; progesterone; endothelial function DIMINISHED CAPACITY OF THE endothelium to generate nitric oxide (NO) has emerged as a primary factor provoking endothelial dysfunction (ECD) (7). Abnormal function of the endothelial nitric oxide synthase (eNOS) system that results in ECD includes: decreased eNOS expression, altered NO signaling, destruction of NO by reactive oxygen species, impaired availability of cofactors, and elevated endogenous NOS inhibitors such as asymmetrical dimethylarginine and advanced glycation end products (23). In addition, the delivery of transported arginine to membrane-bound eNOS, selectively by the cationic amino acid transporter-1 (CAT-1), rather than intra-or extracellular arginine concentration, has been suggested to govern eNOS activity. Indeed, we have previously shown in several different animal models, characterized by endothelial dysfunction and decreased eNOS activity, that CAT-1 activity is diminished due to increase in its phosphorylated (inactive) form (10, 12, 24, 27, 31) . Interestingly, in two well-established experimental models of ECD (renal failure and aging), arginine transport by CAT-1 decreased only in males while females were protected (22, 28) . In contrast, during pregnancy, females lose the ability to maintain adequate endothelial arginine transport velocities by CAT-1, a loss that is associated with increased protein nitration possibly due to posttranslational regulation of CAT-1 by protein kinase C␣ (PKC␣) (24, 30). Our current experiments, which utilized human umbilical vein endothelial cells (HUVEC), were designed to test the hypothesis that female sex hormones modulate CAT-1 activity, thus playing a role in both the gender-and pregnancy-related effects on the L-arginine-eNOS system.
DIMINISHED CAPACITY OF THE endothelium to generate nitric oxide (NO) has emerged as a primary factor provoking endothelial dysfunction (ECD) (7) . Abnormal function of the endothelial nitric oxide synthase (eNOS) system that results in ECD includes: decreased eNOS expression, altered NO signaling, destruction of NO by reactive oxygen species, impaired availability of cofactors, and elevated endogenous NOS inhibitors such as asymmetrical dimethylarginine and advanced glycation end products (23) . In addition, the delivery of transported arginine to membrane-bound eNOS, selectively by the cationic amino acid transporter-1 (CAT-1), rather than intra-or extracellular arginine concentration, has been suggested to govern eNOS activity. Indeed, we have previously shown in several different animal models, characterized by endothelial dysfunction and decreased eNOS activity, that CAT-1 activity is diminished due to increase in its phosphorylated (inactive) form (10, 12, 24, 27, 31) . Interestingly, in two well-established experimental models of ECD (renal failure and aging), arginine transport by CAT-1 decreased only in males while females were protected (22, 28) . In contrast, during pregnancy, females lose the ability to maintain adequate endothelial arginine transport velocities by CAT-1, a loss that is associated with increased protein nitration possibly due to posttranslational regulation of CAT-1 by protein kinase C␣ (PKC␣) (24, 30) . Our current experiments, which utilized human umbilical vein endothelial cells (HUVEC), were designed to test the hypothesis that female sex hormones modulate CAT-1 activity, thus playing a role in both the gender-and pregnancy-related effects on the L-arginine-eNOS system.
MATERIALS AND METHODS
Cell culture and chemicals. Fresh unpassaged HUVEC (female) were obtained from Promo Cell (Heidelberg, Germany). Upon arrival, the cells were cultured according to the manufacturer's instructions in endothelial cell M2 growth medium containing 2% fetal calf serum, 100 g/ml penicillin-streptomycin, and 0.05 g/ml amphotericin B, at 37°C in a humidified atmosphere containing 5% CO2. The medium was changed three times weekly. Cells were used for experiments when they were 70 -80% confluent, between passages 3 and 6. Twenty four hours before the experiments, the incubation medium was changed to 5% bovine serum albumin. 17␤-Estradiol (E2) and progesterone were dissolved in ethanol (final concentration Ͻ10 Ϫ5 %). MAPK inhibitors UA-126 [extracellular signal-regulated kinase (ERK) inhibitor] and SP-600125 [c-Jun NH2-terminal kinase (JNK) inhibitor], and GO-6976 (PKC␣ inhibitor) (3), were all dissolved in dimethyl sulfoxide (final concentration Ͻ10 Ϫ3 %). All reagents were purchased from Sigma-Aldrich (St. Louis, MO), unless indicated otherwise.
L-Arginine uptake in HUVEC. Uptake of radiolabeled L-arginine in HUVEC was measured according to previously described methods (26) . Cells were seeded onto six-well plates (Corning) at a density of 10 6 cells/well. When confluent, cells were washed with 1 ml HEPES buffer, pH 7.4 at 37°C. L- [H 3 ]arginine and L-arginine, in a final concentration of 100 M, were added to a total volume of 1 ml for 1 min. The duration of 1 min was chosen since it was within the linear portion of the uptake curve (data not shown). Transport was terminated by rapidly washing the cells with ice-cold PBS buffer (4 times, 1 ml/well). The cells were then dried and solubilized in 1 ml of 0.5% SDS in 0.5 N NaOH. Lysate (700 l) was used to monitor radioactivity by liquid scintillation spectrometry (Betamatic; Kontron). The remaining 300 l were used for protein content determination by the Lowry method (Lowry Assay Kit; Sigma). To correct for nonspecific uptake or cell membrane binding, additional studies were performed in which HUVEC were incubated with 10 mM unlabeled arginine in HEPES buffer, and the associated radioactivity was subtracted from each data point. Results are expressed as means Ϯ SE of at least five different experiments.
Nitrite/nitrate determination. The level of nitrite (NO2)/nitrate (NO 3) concentrations in the conditioned medium was measured using a nitric oxide detection kit (ENZO Life Sciences) according to the manufacturer's instructions. In brief, following filtration in a 10-kDa spin column (Biovision) 50 l of the culture medium were diluted with 50 l of reaction buffer containing 50 M L-N 6 -(1-iminoethyl)lysine hydrochloride [L-NIL, a selective inducible NOS (iNOS) inhibitor] and mixed with 25 l NADH and 25 l nitrate reductase. After 30 min incubation during which NO3 is reduced to NO 2, Griess reagents [sulfanileamide in hydrochloric acid and N-(1-naphthyl)ethylenediamine in hydrochloric acid] were added to react with NO 2 to yield a diazochromophore. Total NO2 was measured spectrophotometerically at 540 nm. Each sample was analyzed in triplicate, and the concentration of NO2 was calculated by using a calibration curve. Each measurement was corrected for protein content (using the Lowry assay). Results of at least six experiments were used for statistical significance.
Protein quantification by Western blotting. Endothelial CAT-1, PKC␣, phosphorylated PKC␣ (p-PKC-␣), MAPK ERK, phosphorylated ERK (p-ERK), MAPK JNK, and phosphorylated JNK (p-JNK) protein expression were determined by immunoblotting. Cells were separately placed in ice-cold PBS lysis buffer (pH 7.4) containing protease inhibitors (1 mM phenylmethylsulfonyl fluoride, 4.5 M leupeptin, and 5 M aprotinin; ICN Biomedicals), 0.01% Triton X-100, and 0.1% SDS and then mechanically homogenized and left on ice for 45 min. Homogenates were subsequently centrifuged [13,000 revolutions/min (rpm), 10 min, at 4°C], and cell lysates were stored in aliquots at Ϫ80°C. A membrane fraction was obtained by adding to the pellet an equal volume of lysis buffer supplemented by Tween 20 (0.25%) to solubilize. The protein content of each sample was determined by the method of Lowry. Equal amounts of protein (30 g) were prepared in a sample buffer (2% SDS, 0.01% bromophenol blue, 25% glycerol, 0.0625 M Tris·HCl, pH 6.8, and 5% mercaptoethanol) and analyzed on a 7.5% SDS-PAGE. The gel was transferred onto Hybond ECL nitrocellulose membranes (Amersham) and blocked in PBS-Tween 20 (PBS-T) containing 5% nonfat dried milk, at room temperature. Membranes were then incubated with rabbit anti-human CAT-1, ERK, p-ERK, p-PKC␣, and mouse monoclonal antihuman PKC-␣, JNK, and p-JNK antibodies (all from Santa Cruz Biotechnology) for 1 h at room temperature, washed, and incubated with secondary horseradish peroxidase-conjugated goat anti-rabbit and goat anti-mouse antibodies in PBS-T for 1 h. Membranes were subsequently washed three times, 5 min each, in PBS-T. Membranes were then stripped and reprobed with monoclonal anti-␤-actin or glyceraldehyde-3-phosphate dehydrogenase antibodies as an internal control. The reactive bands corresponding to CAT-1, ERK, p-ERK, p-PKC␣, PKC␣, JNK, and p-JNK were detected by enhanced chemiluminescence (Kodak X-Omat AR film) and quantified by densitometry.
Immunoprecipitation studies. Aliquots of endothelial cell lysate (1 ml) from the different experimental groups were used for immunoprecipitation. Each cell lysate sample was incubated with 20 l of anti-CAT-1 antibodies for 2 h at 4°C. Optimal antibody concentration was determined by titration (data not shown). This was followed by addition of 20 l of protein A/G agarose and incubation overnight at 4°C on a rotating device (Santa Cruz Biotechnology). Pellets were collected by centrifugation at 3,000 rpm for 30 s, 4°C. The supernatants were discarded, and each pellet was subsequently washed three times with PBS. After the final wash, the pellets were resuspended in 40 l of 2ϫ electrophoresis sample buffer, boiled for 3 min, and subjected to immunoblotting, as described above, with antibodies against CAT-1 or the phosphorylated tyrosine residue of CAT-1 (Santa Cruz Biotechnology). To estimate the phosphorylation of CAT-1 in the different groups, the density of bands for CAT-1 and its phosphorylated form was analyzed as above. Results are adjusted for CAT-1 levels and expressed in arbitrary units.
Statistical analysis. Values shown in Figs. 1-7 are means Ϯ SE from data obtained from 4 to 10 experiments. ANOVA test was applied for comparisons of means, and then Bonferroni's test was performed. P values Ͻ0.05 were considered to be statistically significant.
RESULTS
Based on our previous reports, the kinetic properties of the arginine transport system in endothelial cells resemble those of CAT-1 (10) .
The first set of experiments was designed to explore the effect of estradiol and progesterone on CAT-1-related arginine transport. Incubating cells with E 2 (50 -100 nM) for 5 or 30 min significantly augmented arginine transport while lower (10 nM) or higher (200 nM) concentrations had no effect (Fig. 1A) . Arginine uptake was unchanged during longer incubation periods (1, 6 , and 24 h) (data not shown). Exposing the cells to progesterone at concentrations of 1 and 100 pM for 5 and 30 min significantly attenuated arginine transport (Fig. 1B) . To explore whether the hormonal effect on arginine transport is mediated through CAT-1, CAT-1 protein levels were studied. We have found that CAT-1 abundance did not alter by exposure to either E 2 (50 nM) or progesterone (1 pM) for 30 min. To unveil a posttranslational effect on CAT-1 activity, hence on arginine transport velocities, we performed immunoprecipitation studies for phosphorylated CAT-1. E 2 induced a profound decrease in p-CAT1 after 30 min while treatment with progesterone for 5 or 30 min resulted in a significantly augmented p-CAT1 protein content (Fig. 2, A and D) . NO 2 /NO 3 generation by cells exposed to either E 2 or progesterone for 30 min in the presence of L-NIL (a selective iNOS inhibitor), with or without L-NAME (a nonselective NOS inhibitor), was used to evaluate NO production by eNOS. The concentration of NO 2 /NO 3 was significantly higher following E 2 treatment than in control, while progesterone substantially decreased NO 2 /NO 3 generation (Fig. 3) .
To identify a specific signal transduction pathway by which E 2 and progesterone affect arginine uptake, we chose to examine PKC-␣, JNK, and ERK1/2, all of which have been previously shown to modulate eNOS or CAT-1 signaling pathways (5, 6, 8, (15) (16) (17) (18) (19) and are regulated by these hormones (5, 13, 14, 25) . Initially, arginine uptake was measured following incubation of HUVEC with inhibitors of these signal transduction pathways. UO-126 (ERK1/2 inhibitor) and SP-600125 (JNK inhibitor) significantly augmented arginine uptake while GO-6976 (PKC␣ inhibitor) had no effect (Fig. 4A) . Next, arginine uptake was determined when cells were exposed to the same agents in the presence of either E 2 or progesterone for 30 min. We have found that arginine transport was significantly increased following coincubation of E 2 and SP-600125 (JNK inhibitor), while neither E 2 and GO-6976 nor E 2 and UO-126 (ERK1/2 inhibitor) had any effect compared with E 2 alone (Fig. 4B) . Cotreatment with progesterone and either GO- 6976, UO-126, or SP-600125 attenuated the decrease in arginine transport compared with progesterone only. The effect of GO-6976 was more pronounced than the other two (Fig. 4C) . Subsequently, Western blotting was performed for PKC␣, JNK, and ERK1/2 and their phosphorylated forms, following incubation of HUVEC with either E 2 or progesterone for 30 min. Cell exposure to E 2 resulted in a significant decrease in ERK phosphrolyation (Fig. 5) while no changes were seen in PKC␣ or JNK (data not shown). Progesterone significantly augmented phosphorylated ERK and phosphorylated PKC␣ protein levels while JNK remained unchanged (Fig. 6, A-D) .
Finally, coincubating HUVEC simultaneously with both E 2 and progesterone for 30 min resulted in a significantly diminished arginine transport (Fig. 7) .
DISCUSSION
The present study demonstrates, for the first time to our knowledge, that the two main female sex hormones, estradiol and progesterone, exert an opposite effect on NO generation in HUVEC through modulation of arginine transport. E 2 was found to augment, whereas progesterone attenuates, arginine transport velocities and NO synthesis. We have also found that these effects are mediated through posttranslational modulation of CAT-1. An exception is the early (5 min) effect of E 2 by which the mechanism remains elusive. Large epidemiological studies show that premenopausal women have less cardiovascular disease and lower cardiovascular morbidity and mortality than men of the same age and that these cardioprotective benefits disappear after menopause (15) . It is widely thought that estrogen exerts protective effects on the cardiovascular system, at least in part, through augmenting NO generation by eNOS (33) . We have previously shown in two experimental models of ECD, namely, aging and renal failure, that in the female gender, in contrast to males, arginine transport is not downregulated (22, (27) (28) (29) (30) ing a positive effect of E 2 on arginine transport and the NOS system, can therefore provide a mechanism to explain the aforementioned phenomenon. In contrast, during pregnancy, arginine transport is significantly inhibited in spite of elevated serum estrogen concentrations (24, 30) . This discrepancy can be explained by two observations made in our current studies. First, E 2 failed to augment arginine transport when concentrations were increased, implying that there is a well-defined E 2 concentration range in which arginine transport is augmented. Increasing the concentration beyond that level results in loss of this effect. This finding is in agreement with previous studies that have demonstrated that estrogens (mainly E 2 ) exhibit a biphasic effect on various biological systems (1, 11, 34) . Second, progesterone provokes an opposite effect on this system. Moreover, when cells were incubated with both hormones, arginine transport was downregulated, suggesting that progesterone dominates over E 2 . Several studies have demonstrated that progesterone antagonizes the effects of E 2 on eNOS, yet this issue remains controversial (2, 4, 8, 16, 19, 20, 35) . In this regard, our findings provide a novel mechanism to explain the opposing effects of these two hormones on endothelial function. Accordingly, E 2 augments arginine transport, and this may provide an explanation of the endothelial resilience in females compared with males. During pregnancy, however, the negative effects of progesterone overcome those of estrogens, resulting in decreased endothelial arginine transport.
We have tried to elucidate a molecular mechanism to explain our findings. Changes in arginine uptake due to both E 2 and progesterone were associated with directional changes in the relative amount of phosphorylated CAT-1 protein. The enhanced arginine transport induced by E 2 was associated with a decrease in phosphorylated CAT-1 while the attenuated arginine transport by progesterone was associated with increased CAT-1 phosphorylation. An exception was the effect of E 2 after 5 min, which did not appear to relate to changes in CAT-1 phosphorylation. One can argue that there are several pathways by which E 2 affects arginine metabolism, and these were not revealed by the current studies. We have previously reported, in four different experimental models characterized by diminished arginine transport, namely hypercholesterolemia, chronic renal failure, pregnancy, and aging in the male rat, a posttranslational modulation of CAT-1 that was associated with upregulation of PKC␣. Namely, PKC␣ increased the fraction of phosphorylated CAT-1, which is the inactive form (12, 24, 28, 29, 31) . Therefore, we chose to look at changes in PKC␣ phosphorylation following incubation with either E 2 or progesterone. Indeed, progesterone produced a significant increase in PKC␣ phosphorylation that can account for the decrease in CAT-1 activity. However, E 2 had no effect. A thorough review of the literature reveals that both MAPKs JNK and ERK1/2 can be modulated by E 2 (13, 14, 25) and positively affect endothelial function (6, 9, 17, 32) , which could indicate a potential CAT-1 involvement. Therefore, we pursued with experiments looking at these proteins as a possible link between E 2 , progesterone, and CAT-1. Inhibitors for both ERK1/2 and JNK were found to augment arginine transport, implying that these enzymes exhibit a constitutive negative effect on CAT-1 activity. However, only ERK1/2 was influenced by both E 2 and progesterone. E 2 decreased ERK1/2 phosphorylation, whereas progesterone did the opposite. The enhanced arginine transport velocities induced by E 2 were not affected by incubation with an ERK1/2 antagonist, which further supports the notion that E 2 effect on CAT-1 is mediated by ERK inhibition.
In conclusion, while estradiol augments arginine transport through modulation of CAT-1 protein via ERK1/2 downregulation, progesterone diminishes CAT-1 activity through activation of both ERK1/2 and PKC␣. These findings may shed light on sexual dimorphism and on the behavior of this system during pregnancy.
Perspectives and Significance
CAT-1, the selective arginine supplier of eNOS, is an important regulator of NO generation by endothelial cells. In the current studies we have shown that estradiol increases, whereas progesterone decreases, NO generation through modulation of CAT-1 activity. These data provide a novel mechanism to explain the effects of female sex hormones on the endothelium and support the therapeutic use of arginine under certain conditions. 
